Scarica l'app Stockscreener
1.21
1.68%
0.02
Pre-mercato:
1.20
-0.01
-0.83%
Precedente Chiudi:
$1.19
Aprire:
$1.21
Volume 24 ore:
241.18K
Relative Volume:
0.41
Capitalizzazione di mercato:
$74.92M
Reddito:
$248.00K
Utile/perdita netta:
$-149.34M
Rapporto P/E:
-0.497
EPS:
-2.4348
Flusso di cassa netto:
$-128.71M
1 W Prestazione:
+0.00%
1M Prestazione:
-10.37%
6M Prestazione:
-26.22%
1 anno Prestazione:
-23.90%
Intervallo 1D:
$1.19
$1.235
Intervallo di 1 settimana:
$1.18
$1.235
Portata 52W:
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Nome
Pliant Therapeutics Inc
Settore
Industria
Telefono
650-481-6770
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.21 | 74.92M | 248.00K | -149.34M | -128.71M | -2.4348 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Ripresa | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Downgrade | Needham | Buy → Hold |
| 2025-03-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Downgrade | Citigroup | Buy → Neutral |
| 2025-02-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-05-18 | Iniziato | Canaccord Genuity | Buy |
| 2023-04-13 | Iniziato | Robert W. Baird | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-07 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Outperform |
| 2022-05-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-11-03 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-20 | Iniziato | BTIG Research | Buy |
| 2021-04-05 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Cowen | Outperform |
| 2020-06-29 | Iniziato | Needham | Buy |
| 2020-06-29 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pliant Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen - MarketBeat
Pliant Therapeutics (PLRX) Initiates Key Clinical Trial for Canc - GuruFocus
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Investing News Network
Pliant Therapeutics begins trial of cancer drug combination By Investing.com - Investing.com Australia
Pliant Therapeutics begins trial of cancer drug combination - Investing.com
New cancer trial starts for patients after immunotherapy stops working - Stock Titan
Pliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72 - MSN
Pliant Therapeutics Inc (FRA:9PT) Stock Price & 30 Year Financial Data - GuruFocus
Wall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Sell - MarketBeat
Pliant Therapeutics (NASDAQ: PLRX) outlines 2026 virtual meeting, board changes and pay vote - Stock Titan
[ARS] PLIANT THERAPEUTICS, INC. SEC Filing - Stock Titan
Pliant Therapeutics, Inc. (PLRX) Presents at AACR Annual Meeting 2026Slideshow (NASDAQ:PLRX) 2026-04-21 - Seeking Alpha
Primary Sclerosing Cholangitis (PSC) Market is expected to Hit - openPR.com
Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-101095 Trials - GuruFocus
Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-1010 - GuruFocus
Pliant Therapeutics (PLRX) Stock: Movement Analysis (Breakout Watch) 2026-04-18Elite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai
Pliant presents updated cancer trial data at AACR meeting By Investing.com - Investing.com South Africa
Pliant Therapeutics presents updated Phase 1 data for PLN-101095 in ICI-refractory tumors - Traders Union
Pliant presents updated cancer trial data at AACR meeting - Investing.com
Pliant Therapeutics : Final AACR 2026 PLN10195 Yap - marketscreener.com
Pliant Therapeutics Says Pln-101095 Generally Well Tolerated; Most Common Trae Was Rash, One Grade 3 Trae Observed - TradingView
Pliant Therapeutics Announces Presentation of Updated Data - GlobeNewswire
Pliant Therapeutics, Inc. 8-K SEC Filing Details for April 14, 2026 – Company Information, Registered Securities, and NASDAQ Listing - Minichart
Pliant Therapeutics Announces Board Retirements and Option Repricing - TipRanks
COO Minnie Kuo’s PLRX options repriced to $1.33 exercise price (PLRX) - Stock Titan
Form 4Statement of changes in beneficial ownership of securities - ADVFN
PLIANT THERAPEUTICS (PLRX) reprices Lily Cheung stock options at $1.33 - Stock Titan
Form 8-KCurrent report - ADVFN
Pliant Therapeutics (PLRX) CEO resets multiple option grants to $1.33 - Stock Titan
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Shares Up 1.6%Should You Buy? - MarketBeat
If You Invested $1,000 in Pliant Therapeutics, Inc. (PLRX) - Stock Titan
Bull Run: Is Pliant Therapeutics Inc subject to activist investor interest2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Inflation Data: Is Pliant Therapeutics Inc still a buy after recent gainsPortfolio Update Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
PLRX Technical Analysis | Trend, Signals & Chart Patterns | PLIANT THERAPEUTICS INC (NASDAQ:PLRX) - ChartMill
[EFFECT] PLIANT THERAPEUTICS, INC. SEC Filing - Stock Titan
Pliant Therapeutics, Inc. (PLRX) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Is Pliant Therapeutics (PLRX) Stock Lagging the Market | Price at $1.36, Up 0.74%High Attention Stocks - Newser
Live Pliant Therapeutics, Inc. (PLRX) Technical Analysis - Traders Union
Pliant Therapeutics (PLRX) Stock Analysis Report | Financials & Insights - Benzinga Japan
PLRX PE Ratio & Valuation, Is PLRX Overvalued - Intellectia AI
Pliant Therapeutics, Inc. (PLRX) Stock Price Prediction for 2026, 2030-2040 - tradersunion.com
PLRX Stock Analysis: Pliant Therapeutics Inc. gains 3.53 percent at 1.32 dollar price point - Newser
Pliant Therapeutics Launches New $50 Million ATM Program - The Globe and Mail
Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):